



---

## **A Short Assessment on Type 2 Diabetes Mellitus: Review Article**

*<sup>1</sup> Susma Morang, <sup>2</sup> Pankaj Chasta, <sup>3</sup> Dr. Gaurav K Sharma, <sup>4</sup> Dr. Kaushal K Chandrul*

<sup>1</sup>Student of B. Pharma, Department of Pharmaceutical Science, Mewar University Gangrar, Chittorgarh, Rajasthan.

<sup>2</sup>Guider, Department of Pharmaceutical Science, Mewar University Gangrar, Chittorgarh, Rajasthan.

<sup>3</sup>HOD, Department of Pharmaceutical Science, Mewar University Gangrar, Chittorgarh, Rajasthan.

<sup>4</sup>Principal, Department of Pharmaceutical Science, Mewar University Gangrar, Chittorgarh, Rajasthan.

---

### **ABSTRACT**

Type two diabetes mellitus is a persistent metabolic disease in which occurrence has been growing step by step all over the world. As a end result of this trend, it is quick turning into an epidemic in some countries of the world with the quantity of humans affected predicted to double in the subsequent decade due to extend in getting old population, thereby including to the already current burden for healthcare providers, mainly in poorly developed countries. This evaluate is based on a search of Medline, the Cochrane Database of Systemic Reviews, and quotation lists of applicable publications. Subject heading and key phrases used encompass kind two diabetes mellitus, prevalence, modern diagnosis, and present day treatment. Only articles in English have been included. Screening and analysis is nonetheless primarily based on World Health Organization (WHO) and American Diabetes Association (ADA) standards which consist of each scientific and laboratory parameters. No therapy has but been observed for the disease; however, cure modalities consist of life-style modifications, treatment of obesity, oral hypoglycemic agents, and insulin sensitizers like metformin, a biguanide that reduces insulin resistance, is nevertheless the advocated first line medicinal drug mainly for overweight patients. Other tremendous medicinal drugs encompass non-sulfonylurea secretagogues, thiazolidinediones, alpha glucosidase inhibitors, and insulin. Recent lookup into the pathophysiology of kind two diabetes mellitus has led to the introduction of new medicinal drugs like glucagon-like peptide 1 analogues: dipeptidyl peptidase-IV inhibitors, inhibitors of the sodium-glucose cotransporter two and 11 $\beta$ -hydroxysteroid dehydrogenase 1, insulin-releasing glucokinase activators and pancreatic-G-protein-coupled fatty-acid-receptor agonists, glucagon-receptor antagonists, metabolic inhibitors of hepatic glucose output and quick-release bromocriptine. Inhaled insulin was once licensed for use in 2006 however has been withdrawn from the market due to the fact of low patronage.

**Keywords:** Type 2 diabetes mellitus; Diagnosis; Management; New drugs system;

---

### **Introduction**

Type 2 diabetes is likely one of the oldest ailments known to man. It was once first stated in Egyptian manuscript about 3000 years ago.

1. In 1936, the big difference between kind 1 and kind
2. Diabetes mellitus was once absolutely made.<sup>2</sup>

Type two diabetes mellitus used to be first described as a component of metabolic syndrome in 1988.<sup>3</sup>

Type two diabetes mellitus (former known as non-insulin based diabetes mellitus) is the most frequent structure of diabetes mellitus characterised by way of hyperglycemia, insulin resistance, and relative insulin deficiency.<sup>4</sup> Type two diabetes mellitus outcomes from interplay between genetic, environmental and behavioral threat factors.<sup>5,6</sup> People dwelling with kind two diabetes mellitus are extra susceptible to more than a few forms of each short- and long-term complications, which regularly lead to their untimely death. This tendency of extended morbidity and mortality is considered in sufferers with kind two DM due to the fact of the commonness of this kind of diabetes mellitus, its insidious onset and late recognition, in particular in resource-poor creating international locations like Africa.<sup>7</sup>

---

### **Epidemiology**

It is estimated that 366 million human beings had diabetes mellitus in 2011; through 2030 this would have risen to 552 million.<sup>8</sup>

The wide variety of humans with type two diabetes mellitus is growing in each united states of america with 80% of humans with diabetes mellitus residing in low- and middle-income countries. DM induced 4.6 million deaths in 2011.<sup>8</sup> It is estimated that 439 million human beings would have kind two diabetes mellitus through the yr 2030.<sup>9</sup>

The incidence of kind two diabetes mellitus varies appreciably from one geographical vicinity to the different qas a end result of environmental and way of life threat factors.<sup>10</sup>

Literature search has proven that there are few statistics on hand on the occurrence of kind two diabetes mellitus in Africa as a whole. Studies examining records tendencies inside Africa factor to proof of a dramatic expand in occurrence in each rural and city setting, and affecting each gender equally.<sup>11</sup>

The majority of the diabetes mellitus burden in Africa seems to be kind 2 diabetes mellitus, with much less than 10% of diabetes mellitus instances being kind 1 diabetes mellitus.<sup>11 A</sup>

2011 Centre for Disease Control and Prevention (CDC) record estimates that diabetes mellitus influences about 25.8 million human beings in the US (7.8% of the population) in 2010 with 90% to 95% of them being type two diabetes mellitus.<sup>12</sup>

It is expected that the occurrence of DM in adults of which type two diabetes mellitus is turning into outstanding will expand in the subsequent two decades and tons of the enlarge will show up in growing nations where the majority of sufferers are aged between forty five and sixty four years.<sup>13</sup> It is projected that the latter will equal or even exceed the former in creating nations, for that reason culminating in a double burden as a result of the contemporary fashion of transition from communicable to non-communicable diseases.<sup>14</sup>

---

## Lifestyle, Genetics, and Medical Conditions

Type two DM is due principally to life-style elements and genetics.<sup>15</sup>

A quantity of life-style elements are regarded to be essential to the development of kind two DM. These are bodily inactivity, sedentary lifestyle, cigarette smoking and beneficant consumption of alcohol.<sup>16</sup>

Obesity has been discovered to make a contribution to about 55% of instances of kind two DM.<sup>17</sup> The multiplied fee of childhood weight problems between the Nineteen Sixties and 2000s is believed to have led to the make bigger in kind 2 DM in young people and adolescents.<sup>18</sup> Environmental toxins might also contribute to the latest will increase in the fee of kind two DM. A susceptible positive correlation has been discovered between the awareness in the urine of bisphenol A, a constituent of some plastics, and the incidence of kind two DM.<sup>19</sup>

There is a robust inheritable genetic connection in kind two DM, having loved ones (especially first degree) with kind two DM will increase the dangers of growing kind two DM substantially. Concordance among monozygotic twins is shut to 100%, and about 25% of those with the disorder have a household records of DM.<sup>20</sup> Recently, genes found to be appreciably related with creating type two DM, encompass TCF7L2, PPARG, FTO, KCNJ11, NOTCH2, WFS1, CDKAL1, IGF2BP2, SLC30A8, JAZF1, and HHEX.

KCNJ11 (potassium inwardly rectifying channel, subfamily J, member 11), encodes the islet ATP-sensitive potassium channel Kir6.2, and TCF7L2 (transcription factor 7-like 2) regulates proglucagon gene expression and for that reason the manufacturing of glucagon-like peptide-1.<sup>21</sup> Moreover, weight problems (which is an unbiased hazard factor for kind two DM) is strongly inherited.<sup>22</sup> Monogenic varieties like Maturity-onset diabetes of the younger (MODY), constitutes up to 5% of cases.<sup>23</sup> There are many scientific prerequisites which can probably supply upward shove to, or exacerbate kind two DM. These include obesity, hypertension, multiplied ldl cholesterol (combined hyperlipidemia), and with the situation frequently termed metabolic syndrome (it is additionally recognised as Syndrome X, Reaven's syndrome).<sup>24</sup>

Other reasons consist of acromegaly, Cushing's syndrome, thyrotoxicosis, pheochromocytoma, continual pancreatitis, cancer, and drugs.<sup>25</sup> Additional elements observed to amplify the hazard of kind 2 DM consist of aging,<sup>26</sup> high-fat diets, and a much less lively lifestyle.<sup>27</sup>

---

## Pathophysiology

Type two DM is characterised by using insulin insensitivity as a end result of insulin resistance, declining insulin production, and eventual pancreatic beta-cell failure.<sup>28,29</sup> This leads to a minimize in glucose transport into the liver, muscle cells, and fats cells. There is an expand in the breakdown of fats with hyperglycemia. The involvement of impaired alpha-cell feature has currently been recognized in the pathophysiology of kind two DM.<sup>30</sup>

As a end result of this dysfunction, glucagon and hepatic glucose levels that upward jostle at some stage in fasting are now not suppressed with a meal. Given insufficient degrees of insulin and elevated insulin resistance, hyperglycemia results. The incretins are vital intestine mediators of insulin release, and in the case of GLP-1, of glucagon suppression.

Although GIP endeavor is impaired in these with kind two DM, GLP-1 insulinotropic outcomes are preserved, and accordingly GLP-1 represents a doubtlessly really helpful therapeutic option.<sup>30</sup> However, like GIP; GLP-1 is unexpectedly inactivated via DPP-IV *in vivo*.

Two therapeutic tactics to this hassle have been developed: GLP-1 analogues with multiplied half-lives, and DPP- IV inhibitors, which forestall the breakdown of endogenous GLP- 1 as properly as GIP.<sup>30</sup> Both training of marketers have proven promise, with possible now not solely to normalize fasting and postprandial glucose tiers however additionally to enhance beta-cell functioning and mass.

Studies are ongoing on the function of mitochondrial dysfunction in the improvement of insulin resistance and etiology of kind two DM.<sup>31</sup> Also very vital is adipose tissue, as endocrine organ hypothesis (secretion of a variety of adipocytokines, i.e., leptin, TNF-alpha, resistin, and adiponectin implicated in insulin resistance and perhaps beta-cell dysfunction).<sup>30</sup>

A majority of persons struggling from kind two DM are obese, with central visceral adiposity. Therefore, the adipose tissue performs a essential position in the pathogenesis of kind two DM. Although the predominant concept used to give an explanation for this hyperlink is the portal/visceral hypothesis giving a key position in increased non-esterified fatty acid concentrations, two new rising theories are the ectopic fats storage syndrome (deposition of

triglycerides in muscle, liver and pancreatic cells). These two hypotheses represent the framework for the find out about of the interaction between insulin resistance and beta-cell dysfunction in kind two DM as nicely as between our obesogenic environment and DM threat in the subsequent decade.<sup>30</sup>

---

## Screening and Diagnosis

Tests for screening and analysis of DM are easily available. The test advocated for screening is the identical as that for making diagnosis, with the end result that a tremendous display screen is equal to a diagnosis of pre-diabetes or DM.<sup>32</sup> Although about 25% of sufferers with kind two DM already have microvascular problems at the time of prognosis suggesting that they have had the disorder for more than 5 years at the time of diagnosis.<sup>33</sup> It is nevertheless based totally on the American Diabetic Association (ADA) recommendations of 1997 or World Health Organization (WHO) National diabetic team criteria of 2006, which is for a single raised glucose analyzing with symptoms (polyuria, polydipsia, polyphagia and weight loss),

otherwise raised values on two occasions, of both fasting plasma glucose (FPG)  $\geq 7.0$  mmol/L (126 mg/dL) or with an oral glucose tolerance check (OGTT), two hours after the oral dose a plasma glucose  $\geq 11.1$  mmol/L (200 mg/dL).<sup>32</sup>

The 1997 ADA tips for analysis of DM center of attention on the FPG, whilst WHO focuses on the OGTT.<sup>32</sup> The glycated hemoglobin (HbA1c) and fructosamine is additionally nevertheless beneficial for determining blood sugar manipulation over time. However, training physicians regularly hire different measures in addition to these recommendations. In July 2009, the International Expert Committee (IEC) advocated the extra diagnostic standards of an HbA1c end result  $\geq 6.5\%$  for DM. This committee recommended that the use of the time period pre-diabetes may additionally be phased out however recognized the range of HbA1c tiers  $\geq 6.0\%$  and  $< 6.5\%$  to pick out these at excessive risk of creating DM.<sup>34</sup> As with the glucose-based tests, there is no particular threshold of HbA1c at which normality ends and DM begins.<sup>32</sup> The IEC has elected to suggest a cut-off factor for DM prognosis that emphasizes specificity, commenting that this balanced the stigma and fee of mistakenly figuring out men and women as diabetic towards the minimal scientific penalties of delaying the analysis in a patient with an HbA1c stage  $< 6.5\%$ .<sup>34</sup>

---

## Management

Through way of life and weight-reduction plan modification. Studies have proven that there was once tremendous discount in the incidence of kind two DM with a aggregate of upkeep of physique mass index of 25 kg/m<sup>2</sup>, eating excessive fibre and unsaturated fats and weight-reduction plan low in saturated and trans-fats and glycemic index, ordinary exercise, abstinence from smoking and average consumption of alcohol.<sup>5,16,35-37</sup> Suggesting that majority of kind two DM can be avoided through life-style modification. Patients with kind two DM need to acquire a scientific nutrition evaluation; life-style suggestions have to be tailor-made according to bodily and useful ability.<sup>38</sup>

---

## Pharmacological Agents Biguanides

Biguanides, of which metformin is the most many times used in obese and chubby patients, suppresses hepatic glucose production, will increase insulin sensitivity, enhances glucose uptake by phosphorylating GLUT-enhancer factor, will increase fatty acid oxidation, and decreases the absorption of glucose from the gastrointestinal tract.<sup>39</sup> Research posted in 2008 suggests similarly mechanism of motion of metformin as activation of AMP-activated protein kinase, an enzyme that performs a function in the expression of hepatic gluconeogenic genes.<sup>40</sup> Due to the challenge of improvement of lactic acidosis, metformin must be used with warning in aged diabetic persons with renal impairment. It has a low incidence of hypoglycemia in contrast to sulfonylureas.<sup>39</sup>

---

## Sulfonylureas

These typically nicely tolerated however due to the fact they stimulate endogenous insulin secretion, they raise a threat of hypoglycemia.<sup>38</sup>

Elderly patients, with DM who are dealt with with sulfonylureas have a 36% expanded chance of hypoglycemia in contrast to younger patients.<sup>41</sup> Glyburide is related with greater costs of hypoglycemia in contrast to glipizide.<sup>42</sup> Some of the threat elements for hypoglycemia are age-related impaired renal function, simultaneous use of insulin or insulin sensitizers, age higher than 60 years, latest clinic discharge, alcohol abuse, caloric restriction, a couple of medicinal drugs or medicinal drugs that potentiate sulfonylurea actions.<sup>43</sup> Use of lengthy performing sulfonylurea such as glyburide must be prevented in aged sufferers with DM and use of short-acting glipizide must be preferred.<sup>38</sup>

---

## Meglitinides

Repaglinide and nateglinide are non-sulfonylurea secretagogues which act on the ATP-dependent K-channel in the pancreatic beta cells thereby stimulating the launch of insulin from the beta cells, comparable to sulfonylurea, even though the binding web site is different.<sup>44</sup>

Meglitinides have a fast onset and a brief period of motion (4-6 hrs) and therefore decrease threat of hypoglycemia. Meglitinides are given earlier than foods for postprandial blood glucose control. Pre-prandial administration approves flexibility in case a meal is neglected without elevated threat of hypoglycemia.<sup>45</sup> Repaglinide is in most cases metabolized in the liver with very minimal quantities excreted by the kidneys and accordingly dose adjustment is no longer vital in sufferers with renal insufficiency barring these with end-stage renal disease.<sup>4</sup>

### ***Thiazolidinediones***

Thiazolidinedione is an insulin sensitizer, selective ligands transcription element peroxisomes proliferator-activated gamma. They are the first tablets to tackle the fundamental hassle of insulin resistance in kind two DM patients,<sup>46</sup> whose category now consists of on the whole pioglitazone after the limited use of rosiglitazone endorsed by Food and Drug Administration (FDA) currently due to multiplied cardiovascular activities suggested with rosiglitazone.<sup>36</sup> Pioglitazone use is no longer related with hypoglycemia and can be used in instances of renal impairment and as consequence nicely tolerated in older adults.

On the other hand, due to issues involving peripheral edema, fluid retention and fracture chance in women, its use can be confined in older adults with DM. Pioglitazone ought to be prevented in aged patients with congestive coronary heart failure and is contraindicated in patients with type III-IV coronary heart failure.<sup>47</sup>

### ***Alpha-Glucosidase Inhibitors***

Acarbose, Voglibose and Miglitol have now not broadly been used to treat kind two DM people however are probable to be protected and effective. These marketers are most advantageous for postprandial hyperglycemia and should be averted in sufferers with big renal impairment. Their use is typically confined due to excessive quotes of side-effects such as diarrhoea and flatulence.<sup>38</sup> Voglibose, which is the most up-to-date of the drugs, has been proven in a learn about to considerably enhance glucose tolerance, in phrases of delayed sickness development and in the number of sufferers who accomplished normoglycemia.<sup>48</sup>

### ***Incretin-Based Therapies***

Glucagon-like peptide 1 (GLP-1) analogues are the basis of incretin-based treatments which are to goal this formerly unrecognized function of DM pathophysiology ensuing in sustained enhancements in glycemic manage and multiplied physique weight control.<sup>49</sup> They are handy for use as monotherapy, as an adjunct to eating regimen and workout or in mixture with oral hypoglycemic marketers in adults with kind two DM. Examples are Exenatide, an incretin mimetic, and Liraglutide.<sup>38</sup> There is no danger of hypoglycemia with the use of GLP-1 treatments (unless mixed with insulin secretagogues). In addition, rising proof suggests incretin-based treatments may additionally have a fine have an effect on on inflammation, cardiovascular and hepatic health, sleep, and the central anxious system.<sup>49</sup>

### ***Dipeptidyl-Peptidase IV Inhibitors***

Dipeptidyl-peptidase (DPP) IV inhibitors inhibit dipeptidyl peptidase-4 (DPP-4), a ubiquitous enzyme that swiftly inactivates both GLP-1 and GIP, enlarge lively tiers of these hormones and, in doing so, improves islet feature and glycemic manage in kind two DM.<sup>50</sup> DPP-4 inhibitors are a new classification of anti-diabetogenic tablets that supply same efficacy to modern treatments. They are fantastic as monotherapy in sufferers inadequately managed with weight loss plan and exercising and as add-on remedy in aggregate with metformin, thiazolidinediones, and insulin. The DPP-4 inhibitors are properly tolerated, elevate a low hazard of producing hypoglycemia and are weight neutral. However, they are extraordinarily expensive.<sup>50</sup> The long-term sturdiness of impact on glycemic manipulate and beta-cell morphology and feature continue to be to be established.<sup>50,51</sup>

### ***Insulin***

Insulin is used on my own or in aggregate with oral hypoglycemicagents. Augmentation remedy with basal insulin is beneficial if some beta phone feature remains. Replacement of basal-bolus insulin is indispensable if beta cellphone exhaustion occurs. Rescue remedy using alternative is essential in instances of glucose toxicity which should mimic the regular launch of insulin with the aid of the beta cells of the pancreas.<sup>52</sup> Insulin comes in injectable types - fast acting, brief acting, intermediate performing and lengthy acting. The lengthy appearing types are much less probably to purpose hypoglycemia in contrast to the quick appearing forms.

### ***Insulin analogues***

Insulin therapy was once restricted in its potential to mimic ordinary physiologic insulin secretion. Traditional intermediate- and long-acting insulins (NPH insulin, lente insulin, and ultralente insulin) are constrained with the aid of inconsistent absorption and peaks of motion that may end result in hypoglycemia.<sup>53,54</sup>

The pharmacokinetic profiles of the new insulin analogues are wonderful from these of the normal insulins, and their onset and intervals of motion vary from speedy to prolonged. Currently, two rapid-acting insulin analogues, insulin lispro and insulin aspart, and one long-acting insulin analogue, insulin glargine, are available.<sup>53,54</sup>

### ***Future in Drug Therapy Inhaled Insulin***

The inhaled structure of swiftly appearing insulin which grew to be reachable in 2006,<sup>55</sup> after it used to be authorised via each the European Medicines Evaluation Agency and FDA for cure of kind 1 and kind 2 DM in adults.<sup>55-57</sup> It is a speedy performing structure of insulin that was once indicated for use in adults with kind 1 and kind two DM and has the advantage of shipping immediately into the lungs. Studies have alternatively shown that inhaled

insulin is as superb as, however no longer higher than short performing insulin.<sup>55</sup> It used to be withdrawn from the market by way of the manufacturer in October 2007 due to terrible sales.

### ***Bromocriptine***

Quick-release bromocriptine has currently been developed for the treatment of kind two DM. However, the mechanism of motion is no longer clear. Studies have proven that they decrease the suggest HbA1c stages by 0.0% to 0.2% after 24 weeks of therapy.<sup>58</sup>

### ***Others***

Inhibitors of the sodium-glucose cotransporter 2, which enlarge renal glucose elimination, and inhibitors of 11 $\beta$ -hydroxysteroid dehydrogenase 1, which decrease the glucocorticoid results in liver and fat. Insulin-releasing glucokinase activators and pancreatic-G-protein-coupled fatty-acid-receptor agonists, glucagon-receptor antagonists, and metabolic inhibitors of hepatic glucose output are being assessed for the motive of improvement of new drug remedy for kind two diabetic patients.<sup>59</sup>

---

## **Conclusion**

Type two DM is a metabolic sickness that can be avoided thru lifestyle modification, food plan control, and manipulate of obese and obesity. Education of the populace is nevertheless key to the manipulate of this emerging epidemic. Novel pills are being developed, but no treatment is on hand in sight for the disease, in spite of new perception into the pathophysiology of the disease. Management ought to be tailor-made to improve the excellent of existence of people with kind two DM

## **References**

---

1. Ahmed AM. History of diabetes mellitus. *Saudi Med J* 2002 Apr;23(4):373-378.
2. Diabetes mellitus history- from ancient to modern times. Available at <http://science.jrank.org/pages/2044/Diabetes-Mellitus.html>. (accessed on 22nd July, 2011)
3. Patlak M. New weapons to combat an ancient disease: treating diabetes. *FASEB J* 2002 Dec;16(14):1853.
4. Maitra A, Abbas AK. Endocrine system. In: Kumar V, Fausto N, Abbas AK (eds). *Robbins and Cotran Pathologic basis of disease* (7th ed) 2005. Philadelphia, Saunders; 1156-1226.
5. Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus: present and future perspectives. *Nature reviews endocrinology*. Available at: [www.nature.com/uidfinder](http://www.nature.com/uidfinder). (Accessed 22nd December 2011)
6. Genetic basis of type 1 and type2 diabetes, obesity, and their complications. *Advances and emerging opportunities in diabetes research: a Strategic Planning report of the DMICC*. [www2.niddk.nih.gov/NR](http://www2.niddk.nih.gov/NR). (Accessed 22nd December 2011).
7. Azevedo M, Alla S. Diabetes in sub-saharan Africa: kenya, mali, mozambique, Nigeria, South Africa and zambia. *Int J Diabetes Dev Ctries* 2008 Oct;28(4):101-108.
8. Global burden of diabetes. International Diabetes federation. *Diabetic atlas fifth edition 2011*, Brussels. Available at <http://www.idf.org/diabetesatlas>. (Accessed 18th December 2011).
9. Chamnan P, Simmons RK, Forouhi NG, Luben R, Khaw Ky, Wareham NJ et al. Incidence of type 2 diabetes using proposed HbA1c diagnostic criteria in the EPIC-Norfolk cohort: Implication for preventive strategies. Available at <http://care.diabetesjournal.org>. (Accessed 19th December 2011).
10. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. *Nature* 2001 Dec;414(6865):782-787.
11. Mbanya JC. The burden of type 2 diabetes mellitus in the African diaspora. Available at [www.medscape.com/view article/560718\\_2](http://www.medscape.com/view article/560718_2)
12. Department of Health and Human Services. Centres for Disease Control and Prevention, 2011. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Available at [http://www.cdc.gov/diabetes/pubs/pdf/ndfs\\_2011.pdf](http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf). Accessed December, 20th 2011).
13. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimate for the year 2000 and projections for 2030. *Diabetes Care* 2004;127(5):1047-1053 .
14. Yach D, Hawkes C, Gould CL, Hofman KJ. The global burden of chronic diseases: overcoming impediments to prevention and control. *JAMA* 2004 Jun;291(21):2616-2622.
15. Ripsin CM, Kang H, Urban RJ. Management of blood glucose in type 2 diabetes mellitus. *Am Fam Physician* 2009 Jan;79(1):29-36.
16. Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. *N Engl J Med* 2001 Sep;345(11):790-797.

17. Prevalence of overweight and obesity among adults with diagnosed Diabetes United States, 1988-1994 and 1999-2000"Centers for Disease Control and Prevention (CDC) (November 2004) MMWR. Morbidity and Mortality Weekly Report; 53(45): 1066-1068.
18. Barlow SE and the Expert committee. Expert committee recommendations regarding the prevention, assessment and treatment of childhood and adolescent overweight and obesity: Summary report. *Paediatrics* 2007;120:S164-S192 .
19. Lang IA, Galloway TS, Scarlett A, Henley WE, Depledge M, Wallace RB, et al. Association of urinary bisphenol A concentration with medical disorders and laboratory abnormalities in adults. *JAMA* 2008 Sep;300(11):1303-1310.
20. Rother KI. Diabetes treatment—bridging the divide. *N Engl J Med* 2007 Apr;356(15):1499-1501.
21. McCarthy MI. Genomics, type 2 diabetes, and obesity. *N Engl J Med* 2010 Dec;363(24):2339-2350.
22. Walley AJ, Blakemore AI, Froguel P. Genetics of obesity and the prediction of risk for health. *Hum Mol Genet* 2006 Oct;15(Spec No 2):R124-R130.
23. Camastra S, Bonora E, Del Prato S, Rett K, Weck M, Ferrannini E; EGIR (European Group for the Study of Insulin Resistance). Effect of obesity and insulin resistance on resting and glucose-induced thermogenesis in man. *Int J Obes Relat Metab Disord* 1999 Dec;23(12):1307-1313.
24. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome—a new worldwide definition. *Lancet* 2005 Sep;366(9491):1059-1062.
25. Powers AC. Diabetes mellitus. In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, Loscalzo J (eds). *Harrison's Principles of Internal Medicine*. 17th ed, New York, McGraw-Hill; 2008: 2275-2304.
26. Jack L Jr, Boseman L, Vinicor F. Aging Americans and diabetes. A public health and clinical response. *Geriatrics* 2004 Apr;59(4):14-17.
27. Lovejoy JC. The influence of dietary fat on insulin resistance. *Curr Diab Rep* 2002 Oct;2(5):435-440.
28. Kahn CR. Banting Lecture. Insulin action, diabetogenes, and the cause of type II diabetes. *Diabetes* 1994 Aug;43(8):1066-1084.
29. Robertson RP. Antagonist: diabetes and insulin resistance—philosophy, science, and the multiplier hypothesis. *J Lab Clin Med* 1995 May;125(5):560-564, discussion 565.
30. Fujioka K. Pathophysiology of type 2 diabetes and the role of incretin hormones and beta-cell dysfunction. *JAAPA* 2007; suppl 3-8.
31. Garcia-Roves PM. Mitochondrial pathophysiology and type 2 diabetes mellitus. *Arch Physiol Biochem* 2011 Jul;117(3):177-187.
32. Cox EM, Elelman D. Test for screening and diagnosis of type 2 diabetes. *Clin Diabetes* 2009;4(27):132-138 .
33. Harris MI, Klein R, Welborn TA, Knudman MW. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. *Diabetes Care* 1992 Jul;15(7):815-819.
34. International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. *Diabetes Care* 2009;32:1-8 .
35. Willi C, Bodenmann P, Ghali WA, Faris PD, Cornuz J. Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. *JAMA* 2007 Dec;298(22):2654-2664.
36. Yoon KH, Lee JH, Kim JW, Cho JH, Choi YH, Ko SH, et al. Epidemic obesity and type 2 diabetes in Asia. *Lancet* 2006 Nov;368(9548):1681-1688.
37. Boffetta P, McLerran D, Chan Y, Manami I, Sinha R, Gupta PC, et al. Body mass index and diabetes mellitus in Asia. A cross sectional pooled analysis of 900,000 individuals in the Asia cohort consortium 2011. Available at [www.plosone.org/article/info](http://www.plosone.org/article/info). (Accessed December 2011).
38. Chiniwala N, Jabbour S. Management of diabetes mellitus in the elderly. *Curr Opin Endocrinol Diabetes Obes* 2011 Apr;18(2):148-152.
39. Collier CA, Bruce CR, Smith AC, Lopaschuk G, Dyck DJ. Metformin counters the insulin-induced suppression of fatty acid oxidation and stimulation of triacylglycerol storage in rodent skeletal muscle. *Am J Physiol Endocrinol Metab* 2006;219(1):182-189 .
40. Kim YD, Park KG, Lee YS, Park YY, Kim DK, Nedumaran B, et al. Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP. *Diabetes* 2008 Feb;57(2):306-314.
41. van Staa T, Abenhaim L, Monette J. Rates of hypoglycemia in users of sulfonylureas. *J Clin Epidemiol* 1997 Jun;50(6):735-741.
42. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Individual sulfonylureas and serious hypoglycemia in older people. *J Am Geriatr Soc* 1996 Jul;44(7):751-755.
43. Scheen AJ. Drug interactions of clinical importance with antihyperglycaemic agents: an update. *Drug Saf* 2005;28(7):601-631.
44. Fuhlerdorff J, Rorsman P, Kofod H, Brand CL, Rolin B, MacKay P, et al. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. *Diabetes* 1998 Mar;47(3):345-351.
45. Blicklé JF. Meglitinide analogues: a review of clinical data focused on recent trials. *Diabetes Metab* 2006 Apr;32(2):113-120.

46. Yki-jarvinen H. Thiazolidinediones. *N Engl J Med* 2004;351(11):1106-1118.
47. Coniff RF, Shapiro JA, Seaton TB, Bray GA. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. *Am J Med* 1995 May;98(5):443-451.
48. Kawamori R, Tajima N, Iwamoto Y, Kashiwagi A, Shimamoto K, Kaku K; Voglibose Ph-3 Study Group. Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. *Lancet* 2009 May;373(9675):1607-1614.
49. Stonehouse AH, Darsow T, Maggs DG. Incretin-based therapies. *J Diabetes* 2011. (published online ahead of print).
50. Pratley RE, Salsali A. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. *Curr Med Res Opin* 2007 Apr;23(4):919-931.
51. Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. *Int J Clin Pract* 2006 Nov;60(11):1454-1470.
52. Mayfield JA, White RD. Insulin therapy for type 2 diabetes: rescue, augmentation, and replacement of beta-cell function. *Am Fam Physician* 2004 Aug;70(3):489-500.
53. Burge MR, Schade DS. Insulins. *Endocrinol Metab Clin North Am* 1997 Sep;26(3):575-598.
54. Cameron CG, Bennett HA. Cost-effectiveness of insulin analogues for diabetes mellitus. *CMAJ* 2009 Feb;180(4):400-407.
55. Rosenstock J, Lorber DL, Gnudi L, Howard CP, Bilheimer DW, Chang PC, et al. Prandial inhaled insulin plus basal insulin glargine versus twice daily biphasic insulin for type 2 diabetes: a multicentre randomised trial. *Lancet* 2010 Jun;375(9733):2244-2253.
56. Black C, Cummins E, Royle P, Philip S, Waugh N. The clinical effectiveness and cost-effectiveness of inhaled insulin in diabetes mellitus: a systematic review and economic evaluation. *Health Technol Assess* 2007 Sep;11(33):1-126.
57. Inhaled insulin and diabetes. *Diabetes monitor*. Information, education, and support for people with diabetes. Available at: [www.diabetesmonitor.com/inhaled.htm](http://www.diabetesmonitor.com/inhaled.htm). (Accessed 21st December 2011).
58. Mikhail N. Quick-release Bromocriptine for Treatment of Type 2 diabetes. *Curr Drug Deliv* 2011. (Published online ahead of print)
59. Tahrani AA, Bailey CJ, Del Prato S, Barnett AH. Management of type 2 diabetes: new and future developments in treatment. *Lancet* 2011 Jul;378(9786):182-197.